Loading...
In a multicenter, phase 2, randomized, placebo-controlled trial, researchers investigated the dose-response relationship of daridorexant (an investigational orexin receptor antagonist) in healthy adults with insomnia. In another randomized placebo-controlled trial, researchers investigated whether suvorexant (an FDA-approved orexin receptor antagonist for insomnia) improved sleep outcomes in adults with mild-to-moderate Alzheimer disease (AD) dementia and insomnia.
In the industry-sponsored daridorexant trial, Dauvilliers and colleagues randomized 360 healthy participants (age, <64) to placebo; 5, 10, 25, or 50 mg daridorexant; or 10 mg zolpidem, for 30 days. Objective sleep outcomes were changes in wake after sleep onset (WASO) and latency …